

Combination pharmacotherapy for the management of pain (2008)

Submission date 29/07/2009	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 03/08/2009	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 05/05/2016	Condition category Nervous System Diseases	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Ian Gilron

Contact details
Department of Anesthesiology
Victory 2 Pavillion
Kingston General Hospital
76 Stuart Street
Kingston
Canada
K7L 2V7
+1 (0)613 548 7827
gilroni@queensu.ca

Additional identifiers

Protocol serial number
MCT-94187; ANAE-151-09

Study information

Scientific Title

A double-blind, randomised controlled trial of nortriptyline, morphine, and their combination for neuropathic pain

Study objectives

A combination of morphine and nortriptyline has superior analgesic efficacy versus either drug alone for reducing neuropathic pain.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Queen's University Research Ethics Board, 23/03/2009

Primary study design

Interventional

Study design

Double-blind randomised three-period crossover trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Neuropathic pain

Interventions

1. Morphine-nortriptyline combination
2. Morphine
3. Nortriptyline

As per a double-dummy, balanced Latin Square design, trial medications are administered orally in three different treatment periods. In each of the three periods, doses of nortriptyline, morphine and the two in combination are gradually titrated - over 24 days - towards each individual maximal tolerated dose and continued at that dose for seven days followed by an 11 day taper-washout period. Ceiling doses are 100 mg daily for both nortriptyline and morphine. Total duration of follow-up is 8 months.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Morphine, nortriptyline

Primary outcome(s)

Daily pain intensity. Patient follow-up for primary and secondary outcomes were recorded during treatment at maximal tolerated dose (i.e. day 25 - 31) for each treatment period.

Key secondary outcome(s)

1. Global pain relief, measures of sedation, constipation, other side effects and maximal tolerated drug doses
2. Short form McGill Pain Questionnaire-2
3. Brief Pain Inventory
4. Beck Depression Inventory
5. 36-item short form health survey (SF-36)
6. Blinding questionnaires
7. Acetaminophen consumption
8. Serum drug levels

Daily pain intensity. Patient follow-up for primary and secondary outcomes were recorded during treatment at maximal tolerated dose (i.e. day 25 - 31) for each treatment period.

Completion date

30/10/2012

Eligibility**Key inclusion criteria**

1. Neuropathic pain
2. Daily moderate (greater than or equal to 4/10) pain for at least 3 months
3. Adults aged 18 to 89 years, either sex
4. Liver function tests: alanine aminotransferase (ALT), aspartate aminotransferase (AST) less than 1.2 times upper limit of normal
5. Creatinine less than 1.5 times upper limit of normal
6. Negative serum beta-human chorionic gonadotrophin (B-HCG) for women of childbearing potential
7. Adequate birth control for all women of child-bearing potential
8. Sufficient cognitive function, visual acuity and English language skills to complete questionnaires and communicate verbally with the nursing staff to permit titration of the study drugs

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Painful condition as severe as, but distinct from presenting neuropathic pain
2. Pregnancy or lactation
3. End-stage kidney or liver disease
4. Moderate to severe heart disease (myocardial infarction [MI] within preceding year, unstable angina, cardiac conduction defect or congestive heart failure)
5. Cardiovascular autonomic neuropathy
6. Postural hypotension greater than 20 mmHg on initial assessment
7. Males with urinary symptoms attributable to benign prostatic hypertrophy
8. Patients who live alone and cannot assure daily contact with a friend, family member or caregiver
9. Angle-closure glaucoma
10. Ongoing administration of monoamine oxidase inhibitors, serotonin-specific reuptake inhibitors, serotonin-norepinephrine inhibitors
11. Any serious psychiatric disorder as diagnosed by a psychiatrist (including bipolar disorder)
12. Seizure disorder
13. Ongoing administration of anticonvulsants which induce cytochrome P450 enzymes (e.g. carbamazepine, oxcarbazepine, barbiturates and phenytoin) as well as rifampin
14. Hypersensitivity to, or previous intolerance of, any of the study medications
15. History of significant abuse of illicit drugs, prescription drugs or alcohol

Date of first enrolment

01/11/2009

Date of final enrolment

30/10/2012

Locations

Countries of recruitment

Canada

Study participating centre

Kingston General Hospital

Kingston

Canada

K7L 2V7

Sponsor information

Organisation

Queen's University (Canada)

ROR

<https://ror.org/02y72wh86>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MCT-94187)

Alternative Name(s)

Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2015		Yes	No